RxDoctor Payments Data

Joel Gelinas, PA

Physician Assistant · Albuquerque, NMNPI 1760417984

Payments from drug & device makers

$1,644in general payments, 2019–2025

Across 51 payments — averaging $32.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SPR Therapeutics, Inc$472
  • Novo Nordisk$236
  • GSK$192
  • Scilex Pharmaceuticals Inc.$163
  • Boehringer Ingelheim$147
  • AstraZeneca$127
  • plus $305 from 10 others

What the payments were for

  • Food & beverage$1,644100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,644 in reported general payments places this provider in the 85th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$73,561
Medicare patients
119
Services billed
2,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl26$17,495
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen339$14,844
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen489$14,099
Fentanyl65$7,171
Xtampza ErOxycodone Myristate16$5,870
BelsomraSuvorexant13$5,793
Morphine Sulfate134$4,924
Gabapentin309$4,832
Pregabalin185$4,720
Oxycodone Hcl186$4,268
Tizanidine Hcl205$3,534
Colchicine46$2,979
Lidocaine30$2,693
Duloxetine Hcl114$1,871
Celecoxib42$1,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$32$5,87016 claims
Scilex Pharmaceuticals Inc.Colchicine$163$2,97946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →